Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
Nature Medicine2014Vol. 20(9), pp. 1027–1034
Citations Over TimeTop 1% of 2014 papers
Christine M. Lovly, Nerina T. McDonald, Heidi Chen, Sandra Ortiz‐Cuaran, Lukas C. Heukamp, Yingjun Yan, Alexandra Florin, Luka Ozretić, Diana Lim, Lu Wang, Chen Zhao, Xi Chen, Lu Wang, Paul K. Paik, Ronglai Shen, Hailing Jin, Reinhard Buettner, Sascha Ansén, Sven Perner, Michael Brockmann, Marc Bos, Jürgen Wolf, Masyar Gardizi, Gavin Wright, Benjamin Solomon, Prudence A. Russell, Toni-Maree Rogers, Yoshiyuki Suehara, Monica Red-Brewer, Rudy Tieu, Elisa de Stanchina, Qingguo Wang, Zhongming Zhao, David H. Johnson, Leora Horn, Kwok‐Kin Wong, Roman K. Thomas, Marc Ladanyi, William Pao
Related Papers
- → The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer(2014)837 cited
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study(2021)17 cited
- → Ceritinib: Breakthrough treatment for ALK-positive metastatic non–small cell lung cancer(2014)
- Review of the use of ceritinib, a newly approved anaplastic lymphoma kinase (ALK) inhibitor, in crizotinib-resistant anaplastic lymphoma kinase-rearranged non-small cell lung cancer(2015)